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Abstract
Background: Recent clinical data suggest statins have transient but significant effects in patients with pulmonary
arterial hypertension. In this study we explored the molecular effects of statins on distal human pulmonary artery
smooth muscle cells (PASMCs) and their relevance to proliferation and apoptosis in pulmonary arterial
hypertension.
Methods: Primary distal human PASMCs from patients and controls were treated with lipophilic (simvastatin,
atorvastatin, mevastatin and fluvastatin), lipophobic (pravastatin) and nitric-oxide releasing statins and studied in
terms of their DNA synthesis, proliferation, apoptosis, matrix metalloproteinase-9 and endothelin-1 release.
Results: Treatment of human PASMCs with selected statins inhibited DNA synthesis, proliferation and matrix
metalloproteinase-9 production in a concentration-dependent manner. Statins differed in their effectiveness, the
rank order of anti-mitogenic potency being simvastatin > atorvastatin > > pravastatin. Nevertheless, a novel nitric
oxide-releasing derivative of pravastatin (NCX 6550) was effective. Lipophilic statins, such as simvastatin, also
enhanced the anti-proliferative effects of iloprost and sildenafil, promoted apoptosis and inhibited the release of
the mitogen and survival factor endothelin-1. These effects were reversed by mevalonate and the isoprenoid
intermediate geranylgeranylpyrophosphate and were mimicked by inhibitors of the Rho and Rho-kinase.
Conclusions: Lipophilic statins exert direct effects on distal human PASMCs and are likely to involve inhibition of
Rho GTPase signalling. These findings compliment some of the recently documented effects in patients with
pulmonary arterial hypertension.
Background
It is recognised that 3-hydroxy-3-methylglutaryl-coen-
zyme A (HMG-CoA) reductase inhibitors (statins) have
beneficial cardiovascular effects beyond cholesterol low-
ering [1,2]. These so-called pleiotropic effects depend
principally on inhibiting the synthesis of the isoprenoid
intermediates farnesylpyrophosphate (FPP) and geranyl-
geranylpyrophosphate (GGPP), which are essential for
the post-translational processing, membrane transloca-
tion and activation of the Ras and Rho GTP-binding
protein families. These GTPases regulate many cellular
functions and couple membrane growth factor receptors
to intracellular pathways that affect cell proliferation
[3,4]. Activation of RhoA and its downstream mediator
Rho-associated kinase is implicated in the pathogenesis
of pulmonary hypertension (PH) and inhibition of the
RhoA/Rho-kinase may also contribute to the beneficial
effects of established therapies, such as sildenafil [5-8].
Statins inhibit RhoA/Rho-kinase signalling by suppres-
sing mevalonate and GGPP synthesis and have been
shown to attenuate the development of PH in several
animal models [9-16]. More importantly, simvastatin
reversed established experimental pulmonary hyperten-
sion [17,18] and this was associated with increased
apoptosis and reduced proliferation of smooth muscle
cells in vascular lesions [9,17]. The addition of simvasta-
tin to sildenafil also reversed hypoxia-induced pulmon-
ary hypertension and remodelling [16]. In keeping with
findings in animal experiments, recent clinical study
using simvastatin in PAH showed transient but signifi-
cant effects on right ventricular mass and NT-proBNP
[19].
Differences have emerged in the protective effect of
HMG-CoA reductase inhibitors in experimental models
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any medium, provided the original work is properly cited.of PH [20,21], raising questions about whether statins as
a class of drugs are capable of inducing similar
responses in the pulmonary vasculature of humans and
laboratory animals. Actually, the potential direct effects
of statins on the growth and survival of PASMCs are
unclear and cells from different regions of the pulmon-
ary vascular bed may vary in their response [22].
We hypothesised that statins have the potential to
directly affect proliferation and apoptosis of distal
human PASMCs. Specifically, we sought to establish (1)
the effect of statins on PASMC proliferation, apoptosis
and production of factors (endothelin-1 and matrix
metalloproteinase-9) implicated in the pathogenesis of
PAH; (2) the anti-proliferative effect of statins when
used in combination with established therapies for PAH
and (3) the intermediates in the mevalonate pathway
responsible for the action of statins.
Methods
Cell isolation and culture
PASMCs were derived from micro-dissected segments
of distal pulmonary arteries (< 1 mm external diameter)
[23,24]. Lung tissues were obtained from patients (8
female/8 male; aged 49.9 ± 2.8 years) undergoing lobect-
omy or pneumonectomy for bronchial carcinoma (n =
3), lung transplantation for idiopathic PAH (IPAH, n =
3), emphysema or fibrotic lung disease (n = 9) and from
unused donor lungs (n = 1). Informed consent and
approval from the Hammersmith Hospitals (Ref. No.
2001/6003) and Royal Brompton & Harefield Hospitals
(Ref. No. 01-210) ethics committees was obtained. Cells
(passages 3 to 12) were phenotyped using immunohisto-
chemical and receptor binding techniques and, like
smooth muscle cells in the medial layer of intact distal
human pulmonary arteries, they expressed a-smooth
muscle actin, calponin, endothelin ETA and ETB recep-
tors and phosphodiesterase type 5 [23,24]. Cells were
quiesced for at least 24 hours in serum-free Dulbeco’s
modified Eagle medium (DMEM) prior to treatment
with statins and other drugs at stated concentrations.
Simvastatin was acquired both as a pro-drug (activated
by alkaline hydrolysis) and in active form, whereas other
statins were obtained as active compounds (Merck Bios-
ciences Ltd., Nottingham, UK). Nitric oxide (NO)-releas-
ing derivatives of pravastatin (NCX 6550) and fluvastatin
(NCX 6553) were provided by the NiCox Research Insti-
tute, Milan, Italy [25]. Involvement of specific signalling
pathways was assessed by examining the ability of exo-
genous mevalonic acid (MVA), squalene, geranylgeranyl-
pyrophosphate (GGPP) and farnesylpyrophosphate (FPP)
to reverse responses to statin treatment and using inhi-
bitors of geranylgeranyl transferase (GGTI-2133), farne-
syl transferase (FTI-277), Rho (exoenzyme C3) and Rho-
kinase (Y-27632) (Merck Biosciences Ltd.).
DNA synthesis
DNA synthesis was assessed by measuring incorporation
of [
3H-methyl]-thymidine (0.25 μCi/well; GE Healthcare,
Little Chalfont, Buck’s, UK) over 24 hours in cells sti-
mulated with recombinant human platelet-derived
growth factor (PDGF, 5 ng/ml; R&D Systems Europe
Ltd., Abingdon, Oxon, UK) [24,26]. Some experiments
were conducted using statins in combination with ilo-
prost (GE Healthcare) and sildenafil (Pfizer Global
Research & Development, Sandwich, Kent, UK).
Cell viability and proliferation
Cell viability was assessed by measuring trypan blue
exclusion and ATP content using a CellTiter-Glo
®
Luminescent cell viability assay (Promega Coporation,
Southampton, UK). Adherent cells were trypsinized and
counted with a multi-chamber haemocytometer.
Apoptosis
Apoptosis was assessed by measuring cytoplasmic his-
tone-associated DNA fragments (Roche Diagnostics Ltd,
Lewis, Sussex, UK) and Hoechst 33342 staining [24,26],
in the presence and absence of the pan-caspase inhibitor
z-VAD-fmk (MP Biomedicals Europe, Illkirch, France).
Endothelin-1 and matrix metalloproteinase-9 production
Production of ET-1 was stimulated with recombinant
human transforming growth factor-b1( T G F - b1, 10 ng/
ml; R&D Systems) for 24 hours and matrix metallopro-
teinase-9 (MMP-9) by tumour necrosis factor-a (TNF-
a, 10 ng/ml) and phorbol 12-myrisate 13-acetate (PMA,
0.1 μM). ET-1 and MMP-9 were measured in condi-
tioned medium using QuantiGlo
® (R&D Systems, UK)
and Biotrack
® immunoassays (GE Healthcare, UK)
respectively [24].
Statistical analysis
Data are expressed as means ± SEM and analysed with
GraphPad Prism version 4.0 (GraphPad Software, San
D i e g o ,C A ) .C o m p a r i s o n sw e r em a d eb yo n e - w a y
ANOVA with Tukey’sp o s tt e s ta n dS t u d e n t ’s t test as
appropriate. A probability of P < 0.05 indicated statisti-
cal significance.
Results
Statin treatment reduces cell proliferation and promotes
apoptosis
Treatment of human PASMCs with PDGF increased
DNA synthesis ~4-fold (P < 0.001) and was attenuated
by statins in a concentration-dependent manner. This
effect was most marked when concentrations above 0.1
μM were used, with 1 μM resulting in significant inhibi-
tion in both IPAH and non-IPAH cells (Figure 1A-B).
However, statins differed in their relative potency, with
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Page 2 of 10a rank order of simvastatin (IC50 0.68 ± 0.09 μM, n =4
isolates) > atorvastatin (IC50 3.11 ± 0.84 μM, n =3i s o -
lates; P = 0.019) > > pravastatin (IC50 >1 0 0μM, n =3
isolates) (Figure 1A). While pravastatin (1-10 μM) failed
to significantly inhibit DNA synthesis the NO-releasing
derivative NCX 6500 was effective at concentrations of
5-10 μM (5-fold higher concentration as compared to
other lipophilic statins) (Figure 1C). Fluvastatin and its
NO-releasing derivative NCX 6553 (1 μM)i n h i b i t e d
DNA synthesis to a similar extent and the effects of all
three compounds were reversed by MVA (Figure 1D).
The inhibitory effect of simvastatin was reversed by
MVA and GGPP, but not by the cholesterol precursor
squalene or by FPP (Figure 2A-B); indicating that the
anti-proliferative effect was due to inhibition of HMG-
CoA reductase and isoprenylation of Rho proteins and
not to the interruption of cholesterol synthesis.
Inhibitors of Rho and Rho-kinase also attenuated DNA
synthesis, implicating Rho/Rho-kinase signalling in the
mitogenic response to PDGF (Figure 2C). In addition,
the anti-proliferative effect of the prostacyclin analogue
iloprost and PDE5 inhibitor sildenafil on human
PASMCs [22,26] was enhanced when used together with
simvastatin, the combined effect being greater than
either agent alone (Figure 2D). Serum-stimulated prolif-
eration of PASMCs from patients with IPAH was also
attenuated by statins, simvastatin being more potent
than atorvastatin at equimolar concentrations (Figure
3A-B). The proportion of adherent, non-viable trypan
blue-stained PASMCs was relatively low (1-2%) and no
significant acute toxic effects were observed with
increasing statin concentrations, as determined by asses-
sing intracellular ATP levels over 24 hours in both the
presence and absence of serum (data not shown).
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Figure 1 Effect of statins on DNA synthesis in human PASMCs. (A-B) Inhibition of DNA synthesis, assessed by PDGF-stimulated (5 ng/ml)
[
3H-methyl]-thymidine incorporation, by statins with rank-order of potency simvastatin = fluvastatin > atorvastatin > > pravastatin. (C-D) Effect of
NO-releasing derivative of pravastatin (NCX 6550), fluvastatin and NO-releasing derivative of fluvastatin (NCX 6553) and prevention by
mevalonate (MVA, 100 μM). MVA alone had no significant effect on DNA synthesis in SF and PDGF-stimulated cells. Data are mean ± SEM from
3-4 distinct PASMC isolates (A-B, D) or replicate values (n = 6) representative of independent experiments (C), using IPAH (B, D), and non-IPAH
(A, C) cells. SF = serum-free untreated controls.
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Page 3 of 10Serum-deprivation increased DNA fragmentation and
this was augmented by simvastatin, fluvastatin and NO-
releasing derivatives of pravastatin (NCX 6500) and flu-
vastatin (NCX 6553), but not by pravastatin (Figure 4A-
B). Theses pro-apoptotic effects were reversed by MVA,
but not by squalene, and mimicked in cells treated with
Y-27632 (Figure 4C-D). The effect of statins was also
prevented by GGPP, but not FPP, and abolished by the
pan-caspase inhibitor z-VAD-fmk (Figure 5A-B).
Furthermore, the pro-apoptotic effect was verified by
assessment of nuclear chromatin condensation in
Hoechst-stained cells (Additional File 1) and accompa-
nied by morphological changes. Cultured cells typically
became rounded and isolated from their neighbours fol-
lowing statin treatment and this was prevented by MVA
(Figure 5C).
Statin treatment inhibits ET-1 release and MMP-9
production
Human PASMCs represent an important site of ET-1
production, particularly when stimulated with cytokines
or growth factors such as TGF-b1 [23,27]. Lipophilic
statins inhibited ET-1 release in a concentration-depen-
dent manner from PASMCs isolated from patients with
I P A H( F i g u r e6 A ) ,a n dt h e s ei n h i b i t o r ye f f e c t sw e r e
reversed by the addition of MVA or GGPP, but not FPP
(Figure 6B). Pravastatin was again found to be ineffec-
tive, whereas the NO-releasing derivative of pravastatin
(NCX 6500), fluvastatin and NCX 6553 all attenuated
ET-1 production (Figure 6C). Inhibition of farnesyl
transferase resulted in non-significant reduction of ET-1
production. Instead inhibition of geranylgeranyl transfer-
ase mimicked the effect of statins (Figure 7A) and,
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Figure 2 Effects of modulating the mevalonate pathway and combination therapy on DNA synthesis in human PASMCs. (A-B) Effect of
simvastatin and reversal by the addition of mevalonate (MVA, 100 μM) or geranylgeranylpyrophosphate (GGPP, 10 μM), but not by squalene
(Squal, 100 μM) or farnesylpyrophosphate (FPP, 10 μM). (C) Inhibitory effect of exoenzyme C3 (C3) and Rho-kinase inhibitor Y-27632. (D)
Inhibitory effect of iloprost in combination with sildenafil or simvastatin and co-treatment with all three agents. Data are mean ± SEM of
replicate values (n = 6), representative of independent experiments, and were obtained using IPAH (D) and non-IPAH (A-C) cells.
Ali et al. Respiratory Research 2011, 12:137
http://respiratory-research.com/content/12/1/137
Page 4 of 10(A) (B)
0
3
6
9
12
15
5% FBS
357 1
Days
0
Simvastatin (1PM)
*
*
***
C
e
l
l
 
n
u
m
b
e
r
 
(
x
 
1
0
4
/
w
e
l
l
)
0
25
50
75
100
0.01 0.1 1 5 10
Simvastatin
Atorvastatin
Statin (PM)
P<0.001
P<0.001
P<0.01
P<0.01
I
n
h
i
b
i
t
i
o
n
 
o
f
 
p
r
o
l
i
f
e
r
a
t
i
o
n
 
(
%
)
Figure 3 Effect of statins on cell counts. (A-B) Inhibition of serum-stimulated (5% FBS) proliferation; simvastatin being more potent than
atorvastatin at equimolar concentrations. Data are mean ± SEM of replicate values, representative of independent experiments with IPAH cells
(A), and of distinct non-IPAH PASMC isolates (n = 4) (B). *, P < 0.05; ***, P < 0.001 versus control cells.
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Figure 4 Pro-apoptotic effect of statins, as assessed by DNA fragmentation. (A) Serum deprivation (SF) increased DNA fragmentation,
compared to PASMCs cultured in presence of serum (5% FBS). Lipophilic statins such as simvastatin, fluvastatin and atorvastatin, but not the
lipophobic pravastatin, promoted apoptosis in serum deprived cells. (B-C) Pro-apoptotic effect of simvastatin, fluvastatin and NO-releasing
derivatives of pravastatin (6550) and fluvastatin (6553) reversed by mevalonate (MVA, 100 μM), but not by squalene (Squal, 100 μM). (D) Pro-
apoptotic effect of exoenzyme C3 (C3) and Rho-kinase inhibitor Y-27632. Data are mean ± SEM of replicate values (n = 4) and representative of
independent experiments with IPAH (A-B) and non-IPAH (C-D) cells. SF = serum free untreated cells.
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Page 5 of 10consistent with signalling via geranylgeranylated pro-
teins, inhibitors of Rho and Rho-kinase also attenuated
ET-1 production (Figure 7B). Stimulation of PASMCs
with TNF-a and PMA markedly induces MMP-9
expression and increases MMP-9 activity in conditioned
medium [24]. Simvastatin attenuated MMP-9 produc-
tion from PASMCs which was reversed by MVA (Figure
7C-D).
As might be expected, the magnitude of statin-
induced responses varied between different human
PASMC isolates. Nonetheless, statins appeared to exhi-
bit reproducible effects in cells from patients with IPAH
and those with other lung diseases or apparently normal
lung tissues.
Discussion
We have shown that statins exhibit several complemen-
tary effects in distal human PASMCs derived from
patients with IPAH as well as other lung diseases. Speci-
fically, lipophilic statins used at concentrations ≥ 1 μM
attenuated proliferation, promoted apoptosis and inhib-
ited production of ET-1 and MMP-9, all of which are
implicated in the pathogenesis of PAH and remodelling
of pulmonary arteries. When used in combination with
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Figure 5 Effect of simvastatin on DNA fragmentation and PASMC morphology. (A-B) Pro-apoptotic effect of simvastatin reversed by
geranylgeranylpyrophosphate (GGPP, 10 μM) and the pan-caspase inhibitor Z-VAD-fmk (Z-VAD, 10 μM), but not by farnesylpyrophosphate (FPP,
10 μM). (C) PASMCs showed characteristic morphological changes (arrows) following simvastatin-treatment (Sim, 1 μM), which were prevented
by co-administration of mevalonate (MVA, 100 μM). Data are mean ± SEM of replicate values (n = 4) and representative of independent
experiments with non-IPAH (A) and IPAH cell isolates (B). SF = serum free untreated cells.
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Page 6 of 10established therapies for PAH, simvastatin (0.5 μM) also
exhibited an additional inhibitory effect on DNA
synthesis.
The anti-proliferative effect of statins was dependent
on inhibition of the mevalonate pathway and forma-
tion of isoprenoids and was selectively reversed by
GGPP and not FPP, suggesting that post-translational
geranylgeranylation of proteins contributes to the
mitogenic effect of PDGF in PASMCs. The Rho family
GTPases are in fact a major target of geranylgeranyla-
tion and the inhibition of Rho and Rho-kinase is con-
sidered to underlie many of the pleiotropic effects of
statins in smooth muscle cells [3]. The anti-mitogenic
effect of Rho and Rho-kinase inhibitors in PASMCs
s u p p o r t st h i sv i e w .M o r e o v e r ,a c t i v a t i o no fR h o A /
Rho-kinase signalling is implicated in the pathogenesis
of PH and inhibition of this pathway attenuates the
development of the disease in experimental models
[5,6,16].
Similar effects of statins in other smooth cells have
been previously reported. The inhibitory effect of sim-
vastatin was mediated by geranylgeranylation of RhoA
but not farnesylation of Ras in bronchial smooth muscle
cells [28]. Mevalonate also reversed anti-proliferative
effect of simvastatin in human bronchial smooth muscle
cells [29]. In addition to the mevalonate pathway, Insu-
lin-like growth factor I/insulin dependent pathway has
been implicated in the inhibition of human vascular
smooth muscle cells proliferation by lovastatin [30].
Established therapies, such as iloprost and sildenafil dis-
play cAMP- and cGMP-dependent anti-proliferative
effects in human PASMCs [22,26] and when used together
with a statin had a greater inhibitory effect than either
agent alone. The use of adjunctive simvastatin in patients
with PAH resulted in short-term reduction of right ventri-
cular mass and marker of cardiac failure supporting the
concept that combination therapies may be of some bene-
fit, although this has not yet been shown to improve
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Figure 6 Effect of statins on TGF-b1-stimulated (10 ng/ml) ET-1 release from human PASMCs. (A) Release of ET-1 in conditioned medium
was attenuated in a concentration-dependent manner by lipophilic statins, but not by pravastatin, with simvastatin being more potent than
atorvastatin. (B) Effect of simvastatin reversed by co-treatment with mevalonate (MVA, 100 μM) or geranylgeranylpyrophosphate (GGPP; 10 μM),
but not by farnesylpyrophosphate (FPP; 10 μM). (C) Inhibitory effect of fluvastatin and NO-releasing derivatives of pravastatin (6550) and
fluvastatin (6553) also reversed by MVA. Data are mean ± SEM of replicate values (n = 4) from representative IPAH cell isolates and expressed
either as the amount of ET-1 detected (per 10
6 cells) in conditioned medium (A) or as a proportion of that measured in control cells treated
with TGF-b1 alone (B-C). SF = serum free untreated cells.
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Page 7 of 10functional capacity [19,31]. Both cAMP and cGMP path-
ways regulate the activity and expression of RhoA in vas-
cular smooth muscle cells [32] and the beneficial effects of
sildenafil and simvastatin in hypoxia-induced PH depend,
at least in part, on the inhibition of RhoA- and Rho-
kinase-dependent functions [8,18].
A number of apoptosis-based strategies have been suc-
cessful in reversing pulmonary vascular remodelling in
animals [33,34], including the use of simvastatin in mono-
crotaline- and hypoxia-induced PH [17,18]. However, the
apoptotic response to statins varies between different spe-
cies and cell types [35] and here we establish that statins
have a pro-apoptotic effect on isolated distal human
PASMCs. The growth of these cultured cells depends on
the autocrine production of ET-1 [24], which is a
recognized survival factor as well as mitogen and protects
against apoptosis in vascular smooth muscle cells [36].
Human PASMCs synthesise substantial amounts of ET-1
when stimulated with TGF-b1 [24] and lipophilic statins
such as simvastatin attenuated ET-1 release. In accordance
with the Rho-dependent regulation of endothelial ET-1
expression by statins [37], the effect was also mimicked by
inhibition of geranylgeranyl transferase, Rho and Rho-
kinase. Thus, a reduction in ET-1 release may contribute
to both the anti-proliferative and pro-apoptotic effects of
statins in PASMCs. Proteolytic enzymes are also impli-
cated in the migration, proliferation and resistance to
apoptosis of PASMCs [38,39] and represent another
potential therapeutic target as PASMCs exhibit increased
gelatinase activity in PAH [40,41] and statins such as
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Figure 7 Modulation of ET-1 and matrix metalloproteinase-9 (MMP-9) production in human PASMCs. (A) Inhibition of geranylgeranyl
transferase (GGTI-2133), rather than farnesyl transferase (FTI-277) mimicked the statin affect, inhibiting ET-1 release. (B) Inhibitory effect of
exoenzyme C3 (C3, 1 μg/ml) and the Rho kinase inhibitor Y-27632 (10 μM) on ET-1 release. (C) Induction of MMP-9 production following dual
stimulation with TNF-a (10 ng/ml) and PMA (0.1 μM) in serum-free (SF) medium. (D) Inhibition of MMP-9 production by simvastatin and reversal
by mevalonate (MVA, 100 μM). Data are mean ± SEM of replicate values that are representative of independent experiments with non-IPAH cells
(A, B, D) and 5-6 distinct PASMC isolates (C).
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Page 8 of 10simvastatin attenuated MMP-9 production in cultured
cells. The precise mechanisms underlying this effect are
not fully understood, but include inhibition of RhoA/Rho-
kinase activation and reduced MMP-9 mRNA expression
[41].
When used at equimolar concentrations, statins dif-
fered in their effectiveness (simvastatin > atorvastatin >>
pravastatin) at inhibiting DNA synthesis, proliferation
and ET-1 production. The ability of statins to inhibit
HMG-CoA reductase activity in other non-hepatic
human cells is considered to vary with their lipophilicity,
simvastatin being 5- to 40-fold more potent than ator-
vastatin and ~600-fold more potent than pravastatin
[42]. Conversely, these statins were broadly equipotent
at inhibiting enzyme activity in a cell-free system [42].
Pravastatin had little or no effect on PASMCs unless it
was linked to a NO-releasing moiety. Besides slowly
releasing NO, this functional group is thought to
increase lipophilicity and aid penetration into cells,
thereby contributing to the MVA-dependent effects of
the NO-releasing derivative NCX 6550 [25]. Thus,
unlike pravastatin, lipophilic fluvastatin and its NO-
releasing derivative NCX 6553 displayed comparable
inhibitory effects on PASMCs. These novel agents have
not been studied before in distal human PASMCs and
could be used as tools in interrogating deranged cellular
pathways in PAH.
It is worth noting that the response of IPAH and non-
IPAH cells to lipophilic statins may be different,
although such a difference was not apparent when sta-
tins were used at concentrations ≥ 1 μM in our studies.
A recent study suggested differences in PDGF (10 ng/
ml) induced cell proliferation between IPAH and non-
IPAH cells when treated with 0.1 μM of simvastatin
[43]. The authors demonstrated greater inhibitory effect
of IPAH than non-IPAH cells. However, in the same
study 1 μM of simvastatin exhibited significant inhibi-
tory effect in non-IPAH cells consistent with our find-
ings. Thus medium to high concentrations of lipophilic
statins affect non-IPAH and IPAH cells equally.
Although the doses of statins used in our experiments
are similar to other studies, such concentrations are
unlikely to be achieved in human plasma. It is conceiva-
ble that lipophilic statins used in clinical doses could
r e s u l ti nac u m u l a t i v er e s p o n s et h r o u g ht h e i re f f e c t so n
a number of cell systems. Speculatively our in vitro
observations could explain the short-term effects of sim-
vastatin in the recent clinical study in PAH [19].
Conclusions
Lipophilic statins directly modulate proliferation, apop-
tosis and the production of ET-1 and MMP-9 in human
PASMCs. These effects are relevant to the pathogenesis
of PAH.
Additional material
Additional File 1: Pro-apoptotic effect of simvastatin, as assessed
by Hoechst staining. (A) Simvastatin-treated PASMCs show characteristic
nuclear condensation (arrows). (B-C) Pro-apoptotic effect of simvastatin in
serum-deprived cells reversed by mevalonate (MVA, 100 μM),
geranylgeranylpyrophosphate (GGPP; 10 μM) and the pan-caspase
inhibitor Z-VAD-fmk (50 μM). Data are mean ± SEM from 3-4 distinct cell
isolates. SF = serum-free untreated cells.
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